The document provides an investor presentation for Biocon from September 2011. It summarizes Biocon as an emerging global biopharmaceutical company focused on developing affordable therapies. It discusses Biocon's business structure, product portfolio across areas like diabetes, oncology and biosimilars. The presentation outlines Biocon's research and development pipeline including oral insulin and monoclonal antibody programs. It also describes Biocon's strategic partnerships with companies like Pfizer, Mylan, Amylin and others. Financial highlights show Biocon's revenues growing over 2008-2011 time period with contributions from areas like research services, branded formulations and biosimilars.
The document provides an overview of Biocon's business including:
1) Biocon is an emerging global biopharmaceutical company focused on developing affordable therapies for chronic diseases like diabetes and cancer.
2) In FY2012, Biocon saw 16% revenue growth and a 27% EBITDA margin, initiated several clinical trials, and formed new strategic partnerships.
3) Biocon has a diversified portfolio spanning small molecules, branded formulations, biosimilars, and research services.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company. In 3 sentences:
Biocon has a portfolio approach across small molecules, biosimilars, branded formulations and novel molecules. It has strategic partnerships for commercialization and research. Financial highlights showed steady revenue and profit growth over 2008-2011, with revenues reaching $402 million and net profit of $74 million in fiscal year 2011.
Indeed, we have changed the paradigm. Take a look at how we performed in the past year and what were the major developments of the past year. Also, gain an understanding of how we intend to take Biocon to the next level.
Biocon reported financial results for the first half of FY13, with 23% revenue growth to INR 1235 crore. Key business segments grew substantially: Biopharma was up 15% to INR 734 crore, Branded Formulations increased 45% to INR 178 crore, and Research Services rose 40% to INR 252 crore. Biocon also made progress in areas like the global Phase 3 trial of its biosimilar insulin, a private equity investment in Syngene, and recognition as a top global employer in the biopharma sector. The company aims to achieve over $1 billion in revenue by FY18 through its five growth drivers.
Biocon provides an investor presentation summarizing its business operations and financial performance. It discusses its focus on developing biosimilars and biologics through research and development efforts. However, it notes that forward-looking statements in the presentation are subject to risks and uncertainties. The presentation provides an overview of Biocon's business segments and product portfolio, and highlights its financial results for the first quarter of the 2014 fiscal year which showed growth across key metrics.
- Biocon is an emerging global biopharmaceutical company focused on developing affordable biologic drugs and biosimilars.
- It has several growth segments including small molecules, biosimilars, novel biologics, and research services.
- Biocon partners with other companies for drug development and commercialization to leverage its capabilities and for global access.
- In 9M FY13, Biocon saw revenue growth of 23% and EBITDA growth driven by performance across business segments.
Biocon provides an investor presentation summarizing its business segments and financial performance. It operates in small molecules, biosimilars, branded formulations, research services, and novel molecules. Revenues have grown from $318 million in FY10 to $487 million in FY14. In Q1 FY15, revenues were $124 million. Biosimilars and research services represent key growth opportunities, while it continues developing a pipeline of novel molecules.
Biocon is an integrated biopharmaceutical company based in India with four business divisions: small molecules and enzymes, branded formulations, research services, and novel molecules. The document discusses Biocon's business overview, growth opportunities in key therapeutic areas like diabetes and oncology, strong partnerships with large pharmaceutical companies, and promising pipeline of novel drug candidates. Biocon has a diversified business model and revenues, and is well-positioned to benefit from the large and growing biopharma industry globally.
The document provides an overview of Biocon's business including:
1) Biocon is an emerging global biopharmaceutical company focused on developing affordable therapies for chronic diseases like diabetes and cancer.
2) In FY2012, Biocon saw 16% revenue growth and a 27% EBITDA margin, initiated several clinical trials, and formed new strategic partnerships.
3) Biocon has a diversified portfolio spanning small molecules, branded formulations, biosimilars, and research services.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company. In 3 sentences:
Biocon has a portfolio approach across small molecules, biosimilars, branded formulations and novel molecules. It has strategic partnerships for commercialization and research. Financial highlights showed steady revenue and profit growth over 2008-2011, with revenues reaching $402 million and net profit of $74 million in fiscal year 2011.
Indeed, we have changed the paradigm. Take a look at how we performed in the past year and what were the major developments of the past year. Also, gain an understanding of how we intend to take Biocon to the next level.
Biocon reported financial results for the first half of FY13, with 23% revenue growth to INR 1235 crore. Key business segments grew substantially: Biopharma was up 15% to INR 734 crore, Branded Formulations increased 45% to INR 178 crore, and Research Services rose 40% to INR 252 crore. Biocon also made progress in areas like the global Phase 3 trial of its biosimilar insulin, a private equity investment in Syngene, and recognition as a top global employer in the biopharma sector. The company aims to achieve over $1 billion in revenue by FY18 through its five growth drivers.
Biocon provides an investor presentation summarizing its business operations and financial performance. It discusses its focus on developing biosimilars and biologics through research and development efforts. However, it notes that forward-looking statements in the presentation are subject to risks and uncertainties. The presentation provides an overview of Biocon's business segments and product portfolio, and highlights its financial results for the first quarter of the 2014 fiscal year which showed growth across key metrics.
- Biocon is an emerging global biopharmaceutical company focused on developing affordable biologic drugs and biosimilars.
- It has several growth segments including small molecules, biosimilars, novel biologics, and research services.
- Biocon partners with other companies for drug development and commercialization to leverage its capabilities and for global access.
- In 9M FY13, Biocon saw revenue growth of 23% and EBITDA growth driven by performance across business segments.
Biocon provides an investor presentation summarizing its business segments and financial performance. It operates in small molecules, biosimilars, branded formulations, research services, and novel molecules. Revenues have grown from $318 million in FY10 to $487 million in FY14. In Q1 FY15, revenues were $124 million. Biosimilars and research services represent key growth opportunities, while it continues developing a pipeline of novel molecules.
Biocon is an integrated biopharmaceutical company based in India with four business divisions: small molecules and enzymes, branded formulations, research services, and novel molecules. The document discusses Biocon's business overview, growth opportunities in key therapeutic areas like diabetes and oncology, strong partnerships with large pharmaceutical companies, and promising pipeline of novel drug candidates. Biocon has a diversified business model and revenues, and is well-positioned to benefit from the large and growing biopharma industry globally.
The document discusses Biocon, an Indian biopharmaceutical company. It summarizes Biocon's business structure and holdings, product portfolio including branded formulations, insulin business in India, and strategic partnerships. Notably, Biocon has entered a global commercialization partnership with Pfizer for biosimilar versions of insulin and insulin analogs, which provides upfront and milestone payments totaling $350 million to Biocon.
1) The Chairman discussed Biocon's focus on developing affordable biopharmaceuticals to make healthcare more accessible globally through five growth verticals.
2) These verticals include small molecules, biosimilars, branded formulations, novel molecules, and integrated research services. Biosimilars and insulin formulations are seen as major growth opportunities.
3) Biocon is augmenting manufacturing, R&D, and marketing capabilities to pursue strong sustainable growth through a new facility in Malaysia and an R&D center in Bangalore. Clinical trials show promise for biosimilar molecules in development.
The document provides results and highlights from Biocon for fiscal year 2012. It discusses Biocon's 16% revenue growth to Rs. 2,148 crores and EBITDA and PAT margins of 27% and 16% respectively. It outlines Biocon's research and development efforts including positive results from a phase 3 clinical trial of Itolizumab for psoriasis. It also discusses Biocon's partnerships with Mylan for biosimilar monoclonal antibodies and its biosimilars portfolio including insulin products in clinical trials. The financial highlights section shows Q4 and full year 2012 results.
This document provides an overview of the Indian pharmaceutical industry, Biocon India Group, and a case study they are considering. It discusses the political, economic, demographic, and technological factors shaping the Indian pharmaceutical industry. It also summarizes India's patent regime and how it has evolved over time. The document then provides background on Biocon Group, including their culture and business units. It outlines the broad questions Biocon is considering regarding their growth strategy and whether to expand their Clinigene clinical trials segment. Potential short and long-term strategies for expansion are discussed.
Biocon FY12 full year results Press Release + Fact SheetBiocon
- Biocon reported a 16% year-over-year increase in revenues for fiscal year 2012 to Rs 2,148 Crores. Net profit was sustained at Rs 338 Crores despite lower licensing income.
- For the fourth quarter of fiscal year 2012, Biocon's revenues increased 30% year-over-year to Rs 6,102 Crores. Net profit increased 15% to Rs 978 Crores.
- Branded formulations grew 39% for the full year and research services grew 29%, driven by new contracts and expansions.
- Biocon delivered 23% year-over-year revenue growth in the first half of FY2013, driven by growth across business verticals like biopharmaceuticals and branded formulations.
- Net profit grew 8% to Rs. 169 Crores compared to the same period last year, despite a 54% increase in research and development spending and higher costs.
- Interim results from a Phase III trial of Biocon's biosimilar rh-Insulin in Europe showed comparable efficacy and safety to the innovator product.
This document provides a situation analysis for a biotech company, Biocon, as it considers launching a new drug called BIOMab to treat head and neck cancer. It analyzes Biocon's capabilities, the market potential, competitors, and alternatives for launching BIOMab. The recommendations are to launch BIOMab immediately after approval to gain a first mover advantage, price it lower than competitors, target top oncologists directly, and promote it through continued medical education for doctors.
Ranbaxy Laboratories is an international pharmaceutical company headquartered in India. It manufactures generic and branded generic drugs and has manufacturing facilities in several countries. The document discusses Ranbaxy's business overview, financial performance from 2004-2008, demand forecasting for 2010, and recommendations. Ranbaxy's sales grew from 2004-2008 but it reported a net loss in 2008 due to issues with the US FDA and forex losses. Demand forecasting using a linear trend line model estimates Ranbaxy's sales in 2010 will be approximately Rs. 47,315.20 crores.
Biocon India Group should expand its operations through Clinigene, its clinical research subsidiary, to capture opportunities in the growing clinical trials market in India. The summary is:
1) Clinigene should expand from bioequivalence and bioavailability studies into clinical trials over 2 years by developing expertise, recruiting qualified staff, and securing clinical trial projects.
2) Factors to consider include maintaining Biocon's public image on ethical issues, protecting its organizational culture, and avoiding expertise divergence from other Biocon operations.
3) A phased expansion over 2 years allows Clinigene to establish itself while Biocon drafts an expansion plan and scouts required resources, minimizing risks to its reputation and operations.
Presentation on Ranbaxy's global business strategy by prashanth kumar gujja.Prashanth Kumar Gujja
Ranbaxy Laboratories is India's largest pharmaceutical company with a worldwide presence in 49 countries. It has manufacturing locations in 8 countries and sells products in over 125 countries. Ranbaxy is among the top 10 global generic pharmaceutical companies. It has over 14,000 employees globally from 50 nationalities. In 2008, Daiichi Sankyo acquired over 51% stake in Ranbaxy Laboratories to gain access to its low-cost generic drug manufacturing capabilities and expand Daiichi's global presence. The acquisition combined Ranbaxy's strengths in generics with Daiichi's research and development expertise.
Ranbaxy has a choice between continuing as a manufacturer of generic drugs or developing proprietary medicines. It could potentially do both by continuing low-cost generic production while beginning to develop patented drugs in India, which has a suitable but improving infrastructure for innovation. Ranbaxy should focus on both developing and developed markets through mergers and strategic partnerships that give it access to foreign markets and resources, especially in geographically and culturally close countries like Russia and China.
Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...Research On Global Markets
Bio-pharmaceutical products are manufactured in the form of complex macromolecules developed through genetic manipulation of living organisms using gene cloning, recombination of DNA and cell fusion. India caters to nearly 50% of the global demand for pharmaceutical products, most of which are based on the usage of biotechnological applications.
This document discusses the development of the biopharmaceuticals industry in India. It provides an overview of the characteristics and growth of the Indian biopharma market, which is valued at over $4 billion and growing 20-25% annually. It also outlines India's advantages for global R&D, including a skilled workforce, lower costs, and efficient clinical trials. The upcoming biosimilars opportunity from patent expiries is highlighted as a major driver. Challenges include financing difficulties and developing human resources excellence. Overall, the biopharma sector is one of India's fastest growing industries.
The document provides profiles of students enrolled in the MBA program at NIPER, including their summer training experiences and credit seminar topics. It lists the names of over 20 students, the organizations they did their summer training at, and the topics of their credit seminars, which generally relate to the pharmaceutical industry. The profiles demonstrate the diverse experiences and areas of focus of NIPER's MBA students.
Ranbaxy Laboratories Ltd. was India’s largest pharmaceutical company in 2006, with global revenue of $1.3 billion. The document discusses Ranbaxy's history and growth strategy under different CEOs from the 1990s-2000s. It summarizes how Parvinder Singh expanded internationally through acquisitions and joint ventures, establishing manufacturing facilities around the world. His successors Devinder Singh Brar and Brian W Tempest continued the global strategy, further growing international sales especially in the US through generic drugs.
Tefen's Supply Chain Breakfast Meeting - Sun PharmaNir Gallner
Benny Klener, Senior VP, Head of Global Operations at Sun Pharma gave a lecture in Tefen's supply chain breakfast meeting, telling about Tefen's supply chain project in Sun Pharma
SBM-Investor-Presentation-April-2022
Sirona Biochem was founded in 2009 by its current Chairman and CEO, Dr. Howard Verrico. The Company’s first transaction was to acquire an exclusive global license to TFChem’s proprietary diabetes drug, the SGLT2 Inhibitor.
Presentation at The 38th JP Morgan Healthcare Conference_EnglishNancy Ning Chen
The document provides an overview of OBI Pharma and its cancer pipeline presented by Michael Chang, Chairman and CEO, at the 38th Annual J.P. Morgan Healthcare Conference on January 15th, 2020. The 3-sentence summary is: OBI Pharma is an oncology company focused on developing novel cancer therapies targeting Globo H and SSEA-4, including its lead product Adagloxad Simolenin vaccine currently in a global Phase 3 trial for triple-negative breast cancer; the company has a diversified pipeline of 4 products in clinical development and proprietary glycan synthesis technologies; Michael Chang reviewed the company's progress and cancer pipeline at the J.P. Morgan Healthcare Conference.
Dr. Kiran Mazumdar Shaw founded Biocon in 1978 with Rs. 10,000 in capital. She has received many prestigious awards for her achievements. Biocon is now India's largest biopharmaceutical company and Dr. Shaw is one of India's richest women. Biocon uses a split business technique to divide its business into subsidiaries that collaborate on pre-clinical discovery, clinical development, and commercialization of health products. This structure drives innovation and provides multiple revenue streams. Biocon employs over 3,600 people and has strategic collaborations with global companies. Its objective is to become a globally distinguished integrated biotechnology enterprise.
1) Alzumab, an antibody developed by Biocon Ltd to treat psoriasis, showed promising results in clinical trials, effectively treating a patient's psoriasis within 8 weeks.
2) Alzumab works through the Th17 immune pathway and has the potential to treat over 100 autoimmune diseases. It was launched in India to treat psoriasis in August 2013.
3) Biocon's development of Alzumab was a breakthrough for the company and Indian innovation, as it was developed through a decade-long process and may establish credibility for Indian clinical research.
Canara Bank, Biocon Foundation and OTTET join hands to strengthen Healthcare ...Biocon
Canara Bank, Biocon Foundation, and OTTET have formed a public-private partnership to strengthen healthcare delivery in Odisha, India. Under this partnership, Biocon Foundation and OTTET will set up electronic diagnostic facilities and e-Health centers at primary health centers in Odisha managed by local entrepreneurs provided financial assistance from Canara Bank. This model aims to improve access to quality healthcare for rural communities by providing diagnostics, telemedicine consultations, and maintaining electronic health records.
The document discusses Biocon, an Indian biopharmaceutical company. It summarizes Biocon's business structure and holdings, product portfolio including branded formulations, insulin business in India, and strategic partnerships. Notably, Biocon has entered a global commercialization partnership with Pfizer for biosimilar versions of insulin and insulin analogs, which provides upfront and milestone payments totaling $350 million to Biocon.
1) The Chairman discussed Biocon's focus on developing affordable biopharmaceuticals to make healthcare more accessible globally through five growth verticals.
2) These verticals include small molecules, biosimilars, branded formulations, novel molecules, and integrated research services. Biosimilars and insulin formulations are seen as major growth opportunities.
3) Biocon is augmenting manufacturing, R&D, and marketing capabilities to pursue strong sustainable growth through a new facility in Malaysia and an R&D center in Bangalore. Clinical trials show promise for biosimilar molecules in development.
The document provides results and highlights from Biocon for fiscal year 2012. It discusses Biocon's 16% revenue growth to Rs. 2,148 crores and EBITDA and PAT margins of 27% and 16% respectively. It outlines Biocon's research and development efforts including positive results from a phase 3 clinical trial of Itolizumab for psoriasis. It also discusses Biocon's partnerships with Mylan for biosimilar monoclonal antibodies and its biosimilars portfolio including insulin products in clinical trials. The financial highlights section shows Q4 and full year 2012 results.
This document provides an overview of the Indian pharmaceutical industry, Biocon India Group, and a case study they are considering. It discusses the political, economic, demographic, and technological factors shaping the Indian pharmaceutical industry. It also summarizes India's patent regime and how it has evolved over time. The document then provides background on Biocon Group, including their culture and business units. It outlines the broad questions Biocon is considering regarding their growth strategy and whether to expand their Clinigene clinical trials segment. Potential short and long-term strategies for expansion are discussed.
Biocon FY12 full year results Press Release + Fact SheetBiocon
- Biocon reported a 16% year-over-year increase in revenues for fiscal year 2012 to Rs 2,148 Crores. Net profit was sustained at Rs 338 Crores despite lower licensing income.
- For the fourth quarter of fiscal year 2012, Biocon's revenues increased 30% year-over-year to Rs 6,102 Crores. Net profit increased 15% to Rs 978 Crores.
- Branded formulations grew 39% for the full year and research services grew 29%, driven by new contracts and expansions.
- Biocon delivered 23% year-over-year revenue growth in the first half of FY2013, driven by growth across business verticals like biopharmaceuticals and branded formulations.
- Net profit grew 8% to Rs. 169 Crores compared to the same period last year, despite a 54% increase in research and development spending and higher costs.
- Interim results from a Phase III trial of Biocon's biosimilar rh-Insulin in Europe showed comparable efficacy and safety to the innovator product.
This document provides a situation analysis for a biotech company, Biocon, as it considers launching a new drug called BIOMab to treat head and neck cancer. It analyzes Biocon's capabilities, the market potential, competitors, and alternatives for launching BIOMab. The recommendations are to launch BIOMab immediately after approval to gain a first mover advantage, price it lower than competitors, target top oncologists directly, and promote it through continued medical education for doctors.
Ranbaxy Laboratories is an international pharmaceutical company headquartered in India. It manufactures generic and branded generic drugs and has manufacturing facilities in several countries. The document discusses Ranbaxy's business overview, financial performance from 2004-2008, demand forecasting for 2010, and recommendations. Ranbaxy's sales grew from 2004-2008 but it reported a net loss in 2008 due to issues with the US FDA and forex losses. Demand forecasting using a linear trend line model estimates Ranbaxy's sales in 2010 will be approximately Rs. 47,315.20 crores.
Biocon India Group should expand its operations through Clinigene, its clinical research subsidiary, to capture opportunities in the growing clinical trials market in India. The summary is:
1) Clinigene should expand from bioequivalence and bioavailability studies into clinical trials over 2 years by developing expertise, recruiting qualified staff, and securing clinical trial projects.
2) Factors to consider include maintaining Biocon's public image on ethical issues, protecting its organizational culture, and avoiding expertise divergence from other Biocon operations.
3) A phased expansion over 2 years allows Clinigene to establish itself while Biocon drafts an expansion plan and scouts required resources, minimizing risks to its reputation and operations.
Presentation on Ranbaxy's global business strategy by prashanth kumar gujja.Prashanth Kumar Gujja
Ranbaxy Laboratories is India's largest pharmaceutical company with a worldwide presence in 49 countries. It has manufacturing locations in 8 countries and sells products in over 125 countries. Ranbaxy is among the top 10 global generic pharmaceutical companies. It has over 14,000 employees globally from 50 nationalities. In 2008, Daiichi Sankyo acquired over 51% stake in Ranbaxy Laboratories to gain access to its low-cost generic drug manufacturing capabilities and expand Daiichi's global presence. The acquisition combined Ranbaxy's strengths in generics with Daiichi's research and development expertise.
Ranbaxy has a choice between continuing as a manufacturer of generic drugs or developing proprietary medicines. It could potentially do both by continuing low-cost generic production while beginning to develop patented drugs in India, which has a suitable but improving infrastructure for innovation. Ranbaxy should focus on both developing and developed markets through mergers and strategic partnerships that give it access to foreign markets and resources, especially in geographically and culturally close countries like Russia and China.
Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...Research On Global Markets
Bio-pharmaceutical products are manufactured in the form of complex macromolecules developed through genetic manipulation of living organisms using gene cloning, recombination of DNA and cell fusion. India caters to nearly 50% of the global demand for pharmaceutical products, most of which are based on the usage of biotechnological applications.
This document discusses the development of the biopharmaceuticals industry in India. It provides an overview of the characteristics and growth of the Indian biopharma market, which is valued at over $4 billion and growing 20-25% annually. It also outlines India's advantages for global R&D, including a skilled workforce, lower costs, and efficient clinical trials. The upcoming biosimilars opportunity from patent expiries is highlighted as a major driver. Challenges include financing difficulties and developing human resources excellence. Overall, the biopharma sector is one of India's fastest growing industries.
The document provides profiles of students enrolled in the MBA program at NIPER, including their summer training experiences and credit seminar topics. It lists the names of over 20 students, the organizations they did their summer training at, and the topics of their credit seminars, which generally relate to the pharmaceutical industry. The profiles demonstrate the diverse experiences and areas of focus of NIPER's MBA students.
Ranbaxy Laboratories Ltd. was India’s largest pharmaceutical company in 2006, with global revenue of $1.3 billion. The document discusses Ranbaxy's history and growth strategy under different CEOs from the 1990s-2000s. It summarizes how Parvinder Singh expanded internationally through acquisitions and joint ventures, establishing manufacturing facilities around the world. His successors Devinder Singh Brar and Brian W Tempest continued the global strategy, further growing international sales especially in the US through generic drugs.
Tefen's Supply Chain Breakfast Meeting - Sun PharmaNir Gallner
Benny Klener, Senior VP, Head of Global Operations at Sun Pharma gave a lecture in Tefen's supply chain breakfast meeting, telling about Tefen's supply chain project in Sun Pharma
SBM-Investor-Presentation-April-2022
Sirona Biochem was founded in 2009 by its current Chairman and CEO, Dr. Howard Verrico. The Company’s first transaction was to acquire an exclusive global license to TFChem’s proprietary diabetes drug, the SGLT2 Inhibitor.
Presentation at The 38th JP Morgan Healthcare Conference_EnglishNancy Ning Chen
The document provides an overview of OBI Pharma and its cancer pipeline presented by Michael Chang, Chairman and CEO, at the 38th Annual J.P. Morgan Healthcare Conference on January 15th, 2020. The 3-sentence summary is: OBI Pharma is an oncology company focused on developing novel cancer therapies targeting Globo H and SSEA-4, including its lead product Adagloxad Simolenin vaccine currently in a global Phase 3 trial for triple-negative breast cancer; the company has a diversified pipeline of 4 products in clinical development and proprietary glycan synthesis technologies; Michael Chang reviewed the company's progress and cancer pipeline at the J.P. Morgan Healthcare Conference.
Dr. Kiran Mazumdar Shaw founded Biocon in 1978 with Rs. 10,000 in capital. She has received many prestigious awards for her achievements. Biocon is now India's largest biopharmaceutical company and Dr. Shaw is one of India's richest women. Biocon uses a split business technique to divide its business into subsidiaries that collaborate on pre-clinical discovery, clinical development, and commercialization of health products. This structure drives innovation and provides multiple revenue streams. Biocon employs over 3,600 people and has strategic collaborations with global companies. Its objective is to become a globally distinguished integrated biotechnology enterprise.
1) Alzumab, an antibody developed by Biocon Ltd to treat psoriasis, showed promising results in clinical trials, effectively treating a patient's psoriasis within 8 weeks.
2) Alzumab works through the Th17 immune pathway and has the potential to treat over 100 autoimmune diseases. It was launched in India to treat psoriasis in August 2013.
3) Biocon's development of Alzumab was a breakthrough for the company and Indian innovation, as it was developed through a decade-long process and may establish credibility for Indian clinical research.
Canara Bank, Biocon Foundation and OTTET join hands to strengthen Healthcare ...Biocon
Canara Bank, Biocon Foundation, and OTTET have formed a public-private partnership to strengthen healthcare delivery in Odisha, India. Under this partnership, Biocon Foundation and OTTET will set up electronic diagnostic facilities and e-Health centers at primary health centers in Odisha managed by local entrepreneurs provided financial assistance from Canara Bank. This model aims to improve access to quality healthcare for rural communities by providing diagnostics, telemedicine consultations, and maintaining electronic health records.
The document describes a photography project at St Luke the Evangelist Primary School aimed at building community partnerships through creative self-expression. Professional development workshops were provided for students, staff, and parents to learn photography skills. Families then participated in activities together to take photos reflecting their values. The photos will be displayed in an art piece representing the school community's identity. The project enhances curriculum learning and relationships by encouraging shared skills and perspectives through photography.
Understanding heart attacks and strokes - by World Health OrganizationBiocon
Heart attacks and strokes are major killers worldwide that are often preventable. A heart attack occurs when blood flow to the heart is blocked, damaging heart muscle, while a stroke happens when blood flow to the brain is interrupted. Both are usually caused by a buildup of fatty deposits in arteries from smoking, an unhealthy diet, and lack of exercise over many years. Taking steps to address risk factors like maintaining a healthy lifestyle can help prevent these conditions.
The document provides tips for quitting tobacco use. It recommends making a plan to quit on a specific date and getting support. Withdrawal symptoms like cravings can occur for weeks after quitting. Nicotine replacements can help with cravings. Tips include avoiding places one used tobacco, keeping busy, and remembering the health benefits of quitting like reduced risk of heart attack and improved circulation and taste. It encourages trying again if the first attempt at quitting fails.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company. It discusses Biocon's vision, business structure, product portfolio including branded formulations in India where it has the number 1 or 2 market share for several drugs. The presentation outlines Biocon's research and development efforts including its pipeline of novel molecules and biologics in diabetes, oncology and immunology. Key pipeline programs discussed are Itolizumab in Phase 3 for rheumatoid arthritis, IN-105 for oral insulin, and partnerships for strategic alliances.
Este documento presenta los ganadores de los trabajos de Navidad realizados por los alumnos de la Asociación de Madres y Padres “San Vicente de Paul” del Colegio San José Infantil Primaria E.S.O Bachiller. Se enumeran los ganadores y segundos premios de cada categoría: Infantil, Primaria 1, Primaria 2 y E.S.O Bachiller.
India's first Int'l Conference on Best Practices in Pharma Microbiology Biocon
This is the first time that Pharmig, an international Pharmaceutical Microbiology think tank based out of the UK is organizing a conference on the "Best Practices in Pharma Microbiology" for the first time in India. You can register
by sending an email to maxine@pharmig.org.uk. For booking a seat for the conference, please visit: http://bit.ly/1J4gtLh
CMD Kiran Mazumdar Shaw Speech at Biocon's 38th Annual General Meeting 2016 Biocon
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive functioning. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
The document provides an investor presentation for Biocon, an emerging global biopharmaceutical company based in India. It discusses Biocon's vision, business structure, product portfolio including branded formulations in India, research and development pipeline including potential new molecules and biosimilars. It also outlines strategic partnerships with Pfizer and Mylan to commercialize biosimilar insulins and monoclonal antibodies globally. Financial highlights show strong revenue and profit growth over the past years and in the first half of fiscal year 2012.
Integrative Research In Oncology On May 15, 2012Biocon
On May 15, 2012, Biocon held a symposium on integrative research in oncology at their research center. Key speakers at the event included the director of the Koch Institute for Integrative Cancer Research, the president of R&D at Biocon, and professors from Harvard Medical School. Panel discussions were held on topics such as translational research with marketed oncology products and personalized cancer treatment approaches.
Biocon investor conference call for the nine months ended 31st December 2011 ...Biocon
This transcript summarizes the Q3 FY12 earnings conference call of Biocon Limited.
[1] Biocon's Chairman and Managing Director Kiran Mazumdar-Shaw discussed the company's performance for the first three quarters of FY12. Revenue grew 15% excluding licensing income, while profits grew nearly 30%. However, licensing income declined sharply from the previous year, resulting in flat overall earnings.
[2] Mazumdar-Shaw highlighted five key growth verticals for Biocon going forward: small molecules, biosimilars, branded formulations, novel molecules, and research services. She expressed confidence in delivering high double-digit growth over the next 5 years through these verticals.
Biocon Q1 FY13 Results Presentation July 2012Biocon
Biocon reported strong financial results for the first quarter of fiscal year 2013, with revenues of 593 Crores and earnings before interest, taxes, depreciation, and amortization (EBITDA) of 139 Crores. All of Biocon's business verticals performed well, with the biopharma business growing 23% year-over-year and the branded formulations business growing 52% year-over-year. Research and development spending increased 75% year-over-year to support clinical trials and product development. Biocon is in discussions for licensing several research programs and expects to finalize agreements going forward.
The document provides an overview of Biocon's financial and operational performance in FY2012, highlighting 16% revenue growth and margins of 27% and 16%. It discusses Biocon's focus on developing affordable biologics and biosimilars through strategic partnerships, as well as its leadership in the Indian insulin market. Biocon is committed to reducing therapy costs for chronic diseases through innovation and global access.
Innovative Science Affordable Medicine - JP Morgan_Biocon Health Conference J...Biocon
Biocon is an emerging global biopharmaceutical company focused on developing affordable products for patients worldwide. It presented on its research and product pipeline at the JP Morgan Healthcare Conference. It has a risk-balanced approach developing generics, biosimilars, novel molecules, and branded formulations. It is leveraging emerging markets which offer high growth opportunities, with 50% of its current revenues coming from emerging markets. Its product pipeline includes several biosimilars including insulin analogs, monoclonal antibodies, and novel molecules like Itolizumab which is in Phase III trials in India for the treatment of psoriasis.
Biocon - Key updates and events
1. Biopharma posts robust revenue growth: 15% YoY
2. Statins: Strong growth in Q2; robust sales of Simvastatin and Pravastatin
3. Focus on improving operational efficiencies to augment capacities
4. Our biosimilar co-marketing Insulins partner, Pfizer has launched in the Indian markets.
The document discusses Pfizer's plans to create the world's premier biopharmaceutical company through acquiring Wyeth. The acquisition will strengthen Pfizer's leadership in key areas like biologics and vaccines, expand its portfolio of growth drivers, and enhance its scientific and manufacturing capabilities. It analyzes how the acquisition advances Pfizer's strategic objectives such as becoming a leader in biologics, entering the vaccines market, and expanding in emerging markets. Charts show how the combined company will have a more diversified portfolio of therapies and platforms.
This document outlines Pfizer's plans to acquire Wyeth to create the world's premier biopharmaceutical company. The acquisition will diversify Pfizer's portfolio and strengthen its leadership in key therapeutic areas and geographies. Pfizer expects the deal to advance its strategic priorities and deliver $2 billion in cost savings by 2011 on top of $4 billion in synergies from the transaction. The all-cash-and-stock deal is valued at $68 billion and will be funded through cash, debt, and Pfizer stock.
This partnership between Biocon and Pfizer will enable Biocon's insulin portfolio to have a global presence. Pfizer will have exclusive commercialization rights for Biocon's biosimilar versions of insulin and insulin analogs globally. Biocon will be responsible for clinical development, manufacturing, supply, and regulatory approvals. The agreement is expected to provide upfront and milestone payments totaling $350 million to Biocon. This partnership will help expand access to affordable treatment options for diabetes patients worldwide.
This report analyzes the worldwide markets for Specialty Enzymes in US$ Million by the following product segments - Specialty Medical Enzymes, Polymerases, Nucleases, and Other Specialty Enzymes. The specific end-use segments discussed are Pharmaceuticals & Diagnostics, and Research/Biotechnology. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 44 companies including many key and niche players such as Advanced Enzymes Technologies Limited, Amano Enzyme Inc., Aureozyme Inc., Biocon Ltd., Biozyme Laboratories Limited, Danisco A/S, Genencor International, Inc., Kinetic Biosystems, Inc., Maxygen Inc, Codexis Inc., Novozymes A/S, Seravac Biotech (Pty) Ltd, Specialty Enzymes & Biochemicals Co., and Verenium Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Biocon Press Conference FY13 Results - April 26, 2013 Biocon
Biocon reported strong financial results for FY13 with 18% revenue growth. Net profit increased 50% due to exceptional items. Key business segments like research services and branded formulations grew over 30%. The company expanded its partnership with Mylan to include development and commercialization of generic insulin analogs. Biocon is progressing several biosimilars programs and expanding globally. It aims to reach $1 billion in sales by 2018 by growing its key business verticals with a focus on emerging markets. The company also reported on its CSR initiatives in healthcare and education in India.
Biocon’s nine months revenue continues to deliver steady growth in fy13Biocon
Biocon, an Indian biopharmaceutical company, reported a 23% year-over-year increase in 9-month revenues to Rs 1,889 Crores, with growth across its biopharma, research services, and branded formulations verticals; the company also received approval for its novel monoclonal antibody Itolizumab and advanced several pipeline programs including biosimilar trials.
Biocon is India's largest biopharmaceutical company, established in 1978. It has grown from an enzyme manufacturing unit to a fully integrated biopharmaceutical enterprise. Biocon has shown strong financial performance over the years, with increasing profits and revenues. However, it has also faced some ethical criticisms over unapproved clinical trials that led to deaths and not following proper procedures. While Biocon's work in biotechnology is innovative, it must focus on conducting all activities ethically to ensure patient safety and trust in its products.
Ezose Sciences Inc. is a relatively new biotech company located in New Jersey that focuses on glycomics and biomarker discovery. It has completed multiple collaborations and utilizes its GlycanMap technology. The pharmaceutical industry is facing pressures to control expenses as major drugs lose patent protection, while biomarkers, personalized medicine, and outsourced research and development represent growth opportunities. Glycomics is an underdeveloped field that could provide insights into disease, drug response and cellular processes.
This document provides a summary of Elliott Sigal's presentation at the 2008 JP Morgan Healthcare Conference on Bristol-Myers Squibb's research and development strategy and pipeline. Sigal discusses BMS's evolution towards a next generation biopharma model focused on an innovative portfolio, selectively integrated business models, and continuous improvement. The presentation highlights BMS's productive pipeline, including recent drug approvals. Sigal also provides updates on key pipeline programs in oncology, transplantation, and diabetes.
The document discusses strategies for developing biosimilars in a cost-effective manner. It notes that while the biopharmaceutical opportunity is large, biosimilar development faces significant challenges related to regulation, manufacturing complexity, and marketing limitations. Companies therefore pursue various strategies like building internal capabilities, outsourcing non-core functions, partnering, and acquisitions. The document uses Reliance Life Sciences as a case study, outlining its multi-pronged approach to developing an integrated biosimilars pipeline and capabilities through both internal investment and external partnerships and deals.
This document summarizes guidelines for biosimilars in India. It begins by defining biosimilars as biologic compounds that are similar but not identical to reference biopharmaceuticals. It then discusses several biosimilar drugs used in cancer treatment such as G-CSF, interferons, and epoetins. While biosimilars have similar mechanisms of action, differences in manufacturing can result in differences in properties. The document concludes by outlining Indian regulatory guidelines for biosimilar approval and the importance of post-marketing safety monitoring to evaluate potential differences from reference drugs.
This document discusses biosimilars, which are biologic medications that are similar but not identical to an original biologic reference medication. It provides background on biosimilars and regulatory guidelines around them. Specifically, it notes that biosimilars take 6-9 years to develop compared to 3 years for generics, and that they require clinical trials to demonstrate safety and efficacy compared to the reference medication. The document also discusses biosimilar guidelines in India and examples of biosimilars used in cancer treatment, noting some differences between biosimilar versions of medications like G-CSF and interferons.
Hi all, with the rigorous secondary research for almost one month helped me to understand basic things about biosimilars and made me do this presentation. Hope u will appreciate it while going through it. thanks.
If anyone in need of this presentation, pls.put ur emial ID in comment box. will be sharing. and please share your thoughts about the presentation. i will be more thankful.
Q1FY14: Biocon Delivers a Healthy Growth of 22% driven by strong traction in ...Biocon
Biocon delivered 22% revenue growth in Q1 FY14 driven by strong performance in its biopharma business. Revenues were ₹723 crores with EBITDA of ₹175 crores and PAT of ₹94 crores. The company's insulin business continues to grow due to an increased geographic footprint in emerging markets. Research services also grew at 26% due to increased demand for integrated services. Biocon plans to launch its second novel biologic, Alzumab, for the treatment of psoriasis in India in the current fiscal year.
applied strategic founder, Dr Richard Littlewood defined success factors for the next 10-year commercial phase of biosimilars at the 8th Biosimilars Congregation, held in London.
Similar to Biocon Investor Presentation_Sept_2011_Q1 (20)
Walk-in Drive at Indore, Madhya Pradesh on Dec 11, 2016 (9AM-2PM)Biocon
This document announces job openings for several positions at a location in Bangalore, India. It provides requirements for Fill Finish Production, Insulin Production, Engineering & Maintenance, and Instrumentation roles. All positions require experience in a pharmaceutical or healthcare setting and working in shifts. Candidates should bring documentation to an interview at a hotel in Indore, Madhya Pradesh.
Walk-in Drive at Aurangabad, Maharashtra on Oct 23, 2016Biocon
Walk-in drive at Aurangabad for positions in Fill finish Production, Fill finish Packing, Engineering & Maintenance, Instrumentation, Insulin Production and Packing inspection.
Date: Oct 23, Sunday (9AM-2PM)
Venue: The Salt, MGM-Sports Club & Stadium, Behind MGM Hospital, N-6 CIDCO, MGM Campus, Aurangabad, 431003
#Job #Recruitment #Biotechnology #Hiring
Biocon Walk in Interviews at Hyderabad on May 22, 2016Biocon
This document provides information about a walk-in interview being held by Biocon Limited in Hyderabad for various positions at their API, Biosimilars, and Injectable facilities in Bangalore. The walk-in will take place on May 22nd, 2016 from 9:00AM to 2:00PM at the Hotel Sree Krishnaa Grand in Hyderabad. Candidates should bring the required documents and register online. A number of positions are listed along with their required qualifications and experience.
Biocon organizing walk-in interviews at VishakhapatnamBiocon
Biocon Walk In at Vishakhapatnam
Venue: -
Integral Institute of Advanced Management (IIAM)
Plot Not 10, Sector 7, MVP Colony, Visakhapatnam - 530 017.
Landmark: Near to CBI Office
Date: Sunday, 22nd May 2016. Time: 9:00AM- 02:00PM
Biocon organizing walk-in interviews at Don Bosco College, Margao, GoaBiocon
Biocon Limited is India's premier biopharma company focused on delivering affordable healthcare globally. It has evolved into an emerging global enterprise serving over 100 partners and customers in 100+ countries. Biocon is ranked #6 among the top 20 global biotech employers by Science Magazine in 2013.
Biocon is looking for experienced professionals for their injectable facilities in Bangalore. Positions include Junior Executive/Executive/Senior Executive/Assistant Manager in Production, Junior Executive/Executive/Senior Executive in Engineering & Maintenance, and Executive/Senior Executive in Validation & Compliance. Candidates should bring documents including photos, CVs, educational and work experience certificates to the walk-in on December 13, 2015 in Margao
Biocon Walkin Interviews Hyderabad 29th November 2015Biocon
All available positions are Bangalore based. This document contains details of the Walkin Interviews scheduled to be held in Hyderabad on the 29th of November, Sunday.Refer this document for available positions and mandatory documents including venue details. Interested candidates can register themselves by clicking here: http://bit.ly/1lNUQGG
New Candidate Registration & Application Process: Navigation from Biocon.comBiocon
To apply for a job at Biocon Ltd., candidates must first create a profile by registering with a username and password. They can then search for suitable jobs, select one, and complete the application in the applicant cockpit. Alternatively, candidates can log in if they already have a profile and search for jobs or continue building their profile before applying. The registration and application process is designed to help candidates create a profile and apply for jobs on the corporate website.
Biocon Bio Waste Disposal Company Statement Biocon
This is the official company statement regarding the trucks carrying waste from Biocon to Terra Firma for disposal as per Pollution Control Board Norms
This document provides details about the available positions for the Biocon Walk In Interviews scheduled to be held on the 28th of June, 2015. Candidates who are unable to attend the Walk In Interviews, are required to register
themselves on the careers page: http://bit.ly/1TRkJ53
Biocon is India's premier biopharma company focused on delivering affordable healthcare globally. It has facilities in Bangalore looking to hire skilled professionals. Positions include production roles in MAbs, fill finish, fermentation, insulin and GPP requiring diplomas or degrees in engineering, chemistry or biotechnology with relevant experience. Other roles include instrumentation, R&D and engineering/maintenance. Candidates should bring documents to a walk-in on November 9th between 9am-4pm or apply online.
Psoriasis is a chronic skin condition caused by genetic and environmental factors. It is characterized by red, scaly patches on the skin. While there is no way to prevent psoriasis, patients can help prevent flare ups by maintaining a healthy lifestyle and avoiding triggers. Treatments range from topical creams and drugs to phototherapy and biological treatments. Biological treatments are very effective but also expensive, while other traditional systems like homeopathy and ayurveda may also help if the treatment is genuine.
World Polio Day is observed annually on October 24th to commemorate the birth of Dr. Jonas Salk, who developed the first polio vaccine. Polio is a highly infectious disease that primarily affects children under 5 and can cause paralysis. The number of polio cases has declined over 99% since 1988 due to a global effort to eradicate the disease through vaccination. India was once considered highly polio-affected but has been polio-free for two years due to a robust vaccination program. However, the risk of polio persists until Pakistan and Bangladesh are also polio-free.
This document discusses avoiding heart attacks and strokes by protecting oneself. It describes several heart conditions including heart failure, which occurs when the heart cannot pump enough blood due to damage from prior heart attacks or other causes. Congenital heart disease refers to defects present at birth, while rheumatic heart disease results from untreated strep throat and damages heart valves over time. Preventing rheumatic fever through prompt antibiotic treatment of strep throat is the best way to avoid rheumatic heart disease.
What are the signs of stroke and what should you doBiocon
Strokes can occur suddenly and cause weakness or numbness on one side of the body, confusion, vision problems, or severe headaches. If someone shows stroke symptoms, call for emergency help immediately. Doctors use scans to diagnose the type of stroke and treat it with medicines to reduce symptoms and prevent future strokes. Rehabilitation after a stroke helps patients regain abilities and adjust to disabilities through exercises and therapies. Adopting a healthy lifestyle and strictly following medical treatment can help prevent additional strokes.
What are the signs of a heart attack and what should you doBiocon
Heart attacks and strokes can strike suddenly and be fatal if assistance is not sought immediately. The document outlines signs of heart attacks and strokes and advises that if any signs are detected, emergency medical help should be contacted without delay. Treatment options are described that may help restore blood flow and minimize damage, but quick action is critical to survival. Lifestyle changes after the event can also help prevent future attacks.
Tobacco use, unhealthy diet, and physical inactivity increase the risk of heart attacks and strokes by leading to high blood pressure, high blood sugar, and high blood fats. These physical problems accelerate the narrowing and hardening of arteries. The document recommends preventing these risks through a healthy lifestyle of not smoking, eating a nutritious diet low in fat and salt, and exercising regularly. Maintaining these habits and seeing a doctor annually can significantly reduce the chances of heart attack and stroke.
Vicinity Jobs’ data includes more than three million 2023 OJPs and thousands of skills. Most skills appear in less than 0.02% of job postings, so most postings rely on a small subset of commonly used terms, like teamwork.
Laura Adkins-Hackett, Economist, LMIC, and Sukriti Trehan, Data Scientist, LMIC, presented their research exploring trends in the skills listed in OJPs to develop a deeper understanding of in-demand skills. This research project uses pointwise mutual information and other methods to extract more information about common skills from the relationships between skills, occupations and regions.
The Rise of Generative AI in Finance: Reshaping the Industry with Synthetic DataChampak Jhagmag
In this presentation, we will explore the rise of generative AI in finance and its potential to reshape the industry. We will discuss how generative AI can be used to develop new products, combat fraud, and revolutionize risk management. Finally, we will address some of the ethical considerations and challenges associated with this powerful technology.
OJP data from firms like Vicinity Jobs have emerged as a complement to traditional sources of labour demand data, such as the Job Vacancy and Wages Survey (JVWS). Ibrahim Abuallail, PhD Candidate, University of Ottawa, presented research relating to bias in OJPs and a proposed approach to effectively adjust OJP data to complement existing official data (such as from the JVWS) and improve the measurement of labour demand.
Falcon stands out as a top-tier P2P Invoice Discounting platform in India, bridging esteemed blue-chip companies and eager investors. Our goal is to transform the investment landscape in India by establishing a comprehensive destination for borrowers and investors with diverse profiles and needs, all while minimizing risk. What sets Falcon apart is the elimination of intermediaries such as commercial banks and depository institutions, allowing investors to enjoy higher yields.
Financial Assets: Debit vs Equity Securities.pptxWrito-Finance
financial assets represent claim for future benefit or cash. Financial assets are formed by establishing contracts between participants. These financial assets are used for collection of huge amounts of money for business purposes.
Two major Types: Debt Securities and Equity Securities.
Debt Securities are Also known as fixed-income securities or instruments. The type of assets is formed by establishing contracts between investor and issuer of the asset.
• The first type of Debit securities is BONDS. Bonds are issued by corporations and government (both local and national government).
• The second important type of Debit security is NOTES. Apart from similarities associated with notes and bonds, notes have shorter term maturity.
• The 3rd important type of Debit security is TRESURY BILLS. These securities have short-term ranging from three months, six months, and one year. Issuer of such securities are governments.
• Above discussed debit securities are mostly issued by governments and corporations. CERTIFICATE OF DEPOSITS CDs are issued by Banks and Financial Institutions. Risk factor associated with CDs gets reduced when issued by reputable institutions or Banks.
Following are the risk attached with debt securities: Credit risk, interest rate risk and currency risk
There are no fixed maturity dates in such securities, and asset’s value is determined by company’s performance. There are two major types of equity securities: common stock and preferred stock.
Common Stock: These are simple equity securities and bear no complexities which the preferred stock bears. Holders of such securities or instrument have the voting rights when it comes to select the company’s board of director or the business decisions to be made.
Preferred Stock: Preferred stocks are sometime referred to as hybrid securities, because it contains elements of both debit security and equity security. Preferred stock confers ownership rights to security holder that is why it is equity instrument
<a href="https://www.writofinance.com/equity-securities-features-types-risk/" >Equity securities </a> as a whole is used for capital funding for companies. Companies have multiple expenses to cover. Potential growth of company is required in competitive market. So, these securities are used for capital generation, and then uses it for company’s growth.
Concluding remarks
Both are employed in business. Businesses are often established through debit securities, then what is the need for equity securities. Companies have to cover multiple expenses and expansion of business. They can also use equity instruments for repayment of debits. So, there are multiple uses for securities. As an investor, you need tools for analysis. Investment decisions are made by carefully analyzing the market. For better analysis of the stock market, investors often employ financial analysis of companies.
^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Duba...mayaclinic18
Whatsapp (+971581248768) Buy Abortion Pills In Dubai/ Qatar/Kuwait/Doha/Abu Dhabi/Alain/RAK City/Satwa/Al Ain/Abortion Pills For Sale In Qatar, Doha. Abu az Zuluf. Abu Thaylah. Ad Dawhah al Jadidah. Al Arish, Al Bida ash Sharqiyah, Al Ghanim, Al Ghuwariyah, Qatari, Abu Dhabi, Dubai.. WHATSAPP +971)581248768 Abortion Pills / Cytotec Tablets Available in Dubai, Sharjah, Abudhabi, Ajman, Alain, Fujeira, Ras Al Khaima, Umm Al Quwain., UAE, buy cytotec in Dubai– Where I can buy abortion pills in Dubai,+971582071918where I can buy abortion pills in Abudhabi +971)581248768 , where I can buy abortion pills in Sharjah,+97158207191 8where I can buy abortion pills in Ajman, +971)581248768 where I can buy abortion pills in Umm al Quwain +971)581248768 , where I can buy abortion pills in Fujairah +971)581248768 , where I can buy abortion pills in Ras al Khaimah +971)581248768 , where I can buy abortion pills in Alain+971)581248768 , where I can buy abortion pills in UAE +971)581248768 we are providing cytotec 200mg abortion pill in dubai, uae.Medication abortion offers an alternative to Surgical Abortion for women in the early weeks of pregnancy. Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman Fujairah Ras Al Khaimah%^^%$Zone1:+971)581248768’][* Legit & Safe #Abortion #Pills #For #Sale In #Dubai Abu Dhabi Sharjah Deira Ajman
Solution Manual For Financial Accounting, 8th Canadian Edition 2024, by Libby...Donc Test
Solution Manual For Financial Accounting, 8th Canadian Edition 2024, by Libby, Hodge, Verified Chapters 1 - 13, Complete Newest Version Solution Manual For Financial Accounting, 8th Canadian Edition by Libby, Hodge, Verified Chapters 1 - 13, Complete Newest Version Solution Manual For Financial Accounting 8th Canadian Edition Pdf Chapters Download Stuvia Solution Manual For Financial Accounting 8th Canadian Edition Ebook Download Stuvia Solution Manual For Financial Accounting 8th Canadian Edition Pdf Solution Manual For Financial Accounting 8th Canadian Edition Pdf Download Stuvia Financial Accounting 8th Canadian Edition Pdf Chapters Download Stuvia Financial Accounting 8th Canadian Edition Ebook Download Stuvia Financial Accounting 8th Canadian Edition Pdf Financial Accounting 8th Canadian Edition Pdf Download Stuvia
Lecture slide titled Fraud Risk Mitigation, Webinar Lecture Delivered at the Society for West African Internal Audit Practitioners (SWAIAP) on Wednesday, November 8, 2023.
2. DISCLAIMER
Certain statements in this release concerning our future growth prospects are
forward-looking statements, which are subject to a number of risks,
uncertainties and assumptions that could cause actual results to differ materially
from those contemplated in such forward-looking statements. Important factors
that could cause actual results to differ materially from our expectations
include, amongst others general economic and business conditions in India, our
ability to successfully implement our strategy, our research and development
efforts, our growth and expansion plans and technological changes, changes in
the value of the Rupee and other currency changes, changes in the Indian and
international interest rates, change in laws and regulations that apply to the
Indian and global biotechnology and pharmaceuticals industries, increasing
competition in and the conditions of the Indian biotechnology and
pharmaceuticals industries, changes in political conditions in India and changes
in the foreign exchange control regulations in India. Neither our company, nor
our directors, nor any of their respective affiliates have any obligation to update
or otherwise revise any statements reflecting circumstances arising after this
date or to reflect the occurrence of underlying events, even if the underlying
assumptions do not come to fruition.
2
3. AGENDA
BIOCON SNAPSHOT
PRODUCTS (BRANDED FORMULATIONS)
RESEARCH & DEVELOPMENT
STRATEGIC ALLIANCES
FINANCIAL HIGHLIGHTS
3
5. VISION
Biocon is an emerging, global Bio-pharmaceutical enterprise
that is focused on developing affordable products and services
for patients, partners and healthcare systems across the world.
Biocon is committed to:
• Reducing therapy costs of chronic diseases. (Diabetes, cancer
and immune-mediated diseases).
• Research and marketing partnerships that provide global
access.
• Leveraging the India cost advantage to deliver high value,
licensable R&D assets.
5
6. BUSINESS STRUCTURE & HOLDINGS
61% | Promoters
~5 % | Employees & ESOP trust Syngene International Ltd, India | 100%
Custom research, drug discovery
~34 % | Public Biocon Clinigene International Ltd, India | 100%
Clinical development
Biocon Research, India | 100%
R&D- Novel Molecules
Biocon Biopharmaceuticals Pvt Ltd | 100%
MAbs and Biosimilars
Biocon SA, Switzerland | 100%
Overseas subsidiary
Biocon Sdn.Bhd, Malaysia | 100%
Overseas subsidiary
NeoBiocon, Dubai | 50%
Overseas subsidiary
6
7. A DIFFERENTIATED BUSINESS MODEL
BALANCED PORTFOLIO :
Products & Services ~ 23%
Revenue
SELF-FINANCED R&D
CAGR and
AND MANUFACTURING
PRODUCTS
STRATEGIC RESEARCH & ~ 17%
MARKETING PARTNERSHIPS
EBITDA CAGR
RISK-BALANCED R&D PIPELINE: (excluding
RESEARCH Axicorp)
SERVICES Biosimilars & Novels
Over the past
COST EFFECTIVE
New Drug Development 5 years
7
8. PRODUCT PORTFOLIO: VERTICALS
New Molecules
New chemistry-
oriented molecules
Biologics
MAbs, IN-105,
Itolizumab
Other novel
Small Molecules biologics
Research Services
Statins, Fidaxomicin, Syngene
Immunosuppressants Clinigene
Insulin Other Bio-pharma
Insulin & analogs Orlistat & Other APIs
Branded
Formulations
Existing Portfolio Diabetology,
Nephrology, Oncotherapeutics,
Comprehensive Care, Cardiology,
Portfolio Expansion Areas
Immunotherapy 8
14. BIOCON’S INSULIN BUSINESS (INDIA)
The 2007-2010 CAGR
Biocon’s ranking Biocon’s market share by
figures for unit sales of
volume:
Insulin 40 IU:
#20 in the OAD market Market: 11% rh-Insulin: 11%
#3 in the rhe-Insulin market Biocon: 13% Glargine: 13%
#2 in the Glargine market NN: 9%
Source : IMS HEALTH – HAS+SSA DATA– SEPT-MAT 10
10 players in
Biocon has the insulin
both OADs space
Pens will be introduced in H2 2011
and insulins
60 of these are in the oral
anti-diabetics space
61 players operate in the
anti-diabetics market
14
16. HIGH POTENTIAL PRODUCT PIPELINE
Diabetes IN 105
Oncology /
Inflammation / ItolizuMAb
Auto immune
Novel Molecules Oncology Anti-EGFR
Oncology Anti-CD 20
Diabetes Peptide Hybrid
Targeted
Oncology
Immunoconjugates
Oncology/Immunology Biosimilar MAbs
Biosimilars
Diabetes Insulin & Analogues rH Insulin, Glargine
rH Insulin, Glargine
Oncology Others GCSF, EPO
2 novel drugs in late stage clinical trials
Oral Insulin : Potentially addressing 300 million diabetes patients worldwide
Anti-CD6 : Data Lock for Phase 3 Psoriasis
16
17. LEAD PROGRAM: ORAL INSULIN IN-105
Drug Highlights
Conjugated peptide
Lower immunogenicity and mitogenicity.
Comparable safety and good clearance profile.
Metabolically equivalent.
Monotherapy.
Combination therapy with metformin,
sulfonylurea, PPAR agonists, DPP4i.
Pre-meal insulin in combination with
basal insulins.
Proof of Concept : Stable tablet formulation.
Established oral delivery
17
18. IN-105 INDIA PHASE III RESULT SUMMARY
SECONDARY END POINTS
Efficacy – Secondary Endpoints
Statistically significant reduction in PPG during STM
Significant reduction in SMBG post prandial glucose excursion
Safety – Secondary Endpoints
No clinically significant hypoglycemia
Very low immunogenicity
No neutralizing antibodies detected
No effect on liver enzymes
No effect on lipid profiles
No effect on renal function
Efficacy – Primary Endpoint
Change in Hb1Ac for IN-105 not statistically significant X
due to higher than anticipated placebo effect 18
19. ANTI-CD6 MAb: T1h
Drug Highlights
Target CD6 o.4mg/kg once in 4 weeks
is a type 1 cell membrane glycoprotein belonging to the
scavenger receptor cysteine-rich (SRCR) super family group B.
CD6 is predominantly expressed by
T cells & a B cell subset. Day 1 Day 29
CD6 binds ALCAM (activated leukocyte cell adhesion molecule)
which is expressed on:
Activated T, cells, B cells & monocytes.
Skin fibroblasts, keratinocytes, rheumatoid arthritis synovium.
0.8mg/kg once in 4 weeks
Drug Development
Day 1 Day 57
Data lock for Phase 2/3 clinical trial in Psoriasis done. Data
analysis ongoing.
Phase 1/2 double blind
Planned trial in MS.
Phase 2/3 double blind trial
in RA by end of 2011.
19
22. BIOSIMILARS PARTNERSHIP: PFIZER
Insulin and Insulin analogs
Combines Biocon's research and manufacturing
capabilities with Pfizer's global marketing prowess
Global agreement for the Pfizer will have exclusive Biocon will be
commercialization of Biocon's rights (with some responsible for clinical
biosimilar versions of Insulin exceptions) to development,
and Insulin Analog products: commercialize these manufacture, supply,
rh- Insulin, Glargine, Aspart, products globally. and regulatory
and Lispro. approvals.
Upfront from Pfizer USD 100 mn
+ New manufacturing facility setup milestone payments 100 USD mn
+Development, regulatory & launch milestone payments 150 USD mn
+Payments linked to supplies.
+ Payments linked to global sales.
22
23. GLOBAL INSULIN MARKET (2010)
Total 2010 Insulin Market USD ~15 bn ~ USD 20 bn in 2020
Growth forecast of ~6% per annum*
*Factoring the advent of Biosimilar Insulins
Sources: Biocon’s estimates complied from Industry reports
23
24. BIOSIMILARS PARTNERSHIP: MYLAN
Monoclonal Antibodies (MAbs)
Combines Biocon's R&D and manufacturing of novel
biologics/bio-generics with Mylan’s regulatory and
commercialization capabilities in the US and Europe
Exclusive Collaboration is for a Mylan will have Biocon and Mylan
collaboration for basket of products exclusive to have co-
development and with patents expiring commercialization exclusive
commercialization between 2014-18. rights in the commercialization
of complex regulated markets; rights in other
biogenerics and Mylan and Biocon to profits to be markets.
biosimilars, MAbs in share development shared.
particular. and capital costs.
.
Current market size for product portfolio in 2010 is ~USD 20 bn
24